Home > Rheumatology > ACR 2019 > Late-Breaking Abstracts > Lowest risk of infection after therapy with an IL-12/IL-23 blocker

Lowest risk of infection after therapy with an IL-12/IL-23 blocker

Presented By
Dr Yinzhu Jin, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA
Conference
ACR 2019
Trial
Cohort study
In a cohort study using data from 2 large US claims databases, researchers assessed the comparative risk of serious infection during the use of biologics in patients with psoriasis and psoriatic arthritis (PsA) [1]. Although the risk of serious infections during the use of small molecules and biologic drugs is a major concern when treating patients with psoriasis or PsA, little is known on the comparative risk of infection among newer medications. To shed light on this important question, Dr Yinzhu Jin (Brigham and Women´s Hospital and Harvard Medical School, Boston, USA) and co-workers conducted a cohort study using the 2 large US databases MarketScan and Optum. They identified patients treated with ustekinumab, secukinumab, ixekizumab, or TNF inhibitors, and the immune modulator apremilast. Patients were required to have psoriasis or PsA diagnosis reported on consecutative occasions over 6 months or variant thereof. Those with a known recent serious infe...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on